Cargando…
Treatable Mechanisms in Asthma
Asthma is a heterogeneous condition, but firm identification of heterogeneity-focused treatments is still lacking. Dividing patients into subgroups of asthma pheno-/endotypes based on combined clinical and cellular biological characteristics and linking them to targeted treatments could be a potenti...
Autores principales: | Cazzola, Mario, Ora, Josuel, Cavalli, Francesco, Rogliani, Paola, Matera, Maria Gabriella |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956930/ https://www.ncbi.nlm.nih.gov/pubmed/33570719 http://dx.doi.org/10.1007/s40291-021-00514-w |
Ejemplares similares
-
Might It Be Appropriate to Anticipate the Use of Long-Acting Muscarinic Antagonists in Asthma?
por: Cazzola, Mario, et al.
Publicado: (2023) -
New Avenues for Phosphodiesterase Inhibitors in Asthma
por: Matera, Maria Gabriella, et al.
Publicado: (2021) -
An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease
por: Cazzola, Mario, et al.
Publicado: (2021) -
Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis
por: Rogliani, Paola, et al.
Publicado: (2019) -
Airflow obstruction: is it asthma or is it COPD?
por: Rogliani, Paola, et al.
Publicado: (2016)